Technical Analysis for NGNE - Neurogene, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 11.62% | |
| Pocket Pivot | Bullish Swing Setup | 11.62% | |
| Volume Surge | Other | 11.62% |
| Alert | Time |
|---|---|
| Up 10% | about 4 hours ago |
| Up 1 ATR | about 5 hours ago |
| Up 5% | about 5 hours ago |
| 60 Minute Opening Range Breakout | about 8 hours ago |
| Rose Above Previous Day's High | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/08/2024
Neurogene, Inc. Description
The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and by designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Rare Diseases Gene Therapy Medical Genetics Central Nervous System Disorders Genetic Engineering Gene Delivery Molecular Genetics Neurological Diseases Transgene
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 53.0 |
| 52 Week Low | 12.2 |
| Average Volume | 113,047 |
| 200-Day Moving Average | 26.92 |
| 50-Day Moving Average | 34.12 |
| 20-Day Moving Average | 36.14 |
| 10-Day Moving Average | 33.91 |
| Average True Range | 3.12 |
| RSI (14) | 61.98 |
| ADX | 18.75 |
| +DI | 33.00 |
| -DI | 19.36 |
| Chandelier Exit (Long, 3 ATRs) | 35.16 |
| Chandelier Exit (Short, 3 ATRs) | 39.05 |
| Upper Bollinger Bands | 43.54 |
| Lower Bollinger Band | 28.75 |
| Percent B (%b) | 0.8 |
| BandWidth | 40.92 |
| MACD Line | 0.12 |
| MACD Signal Line | -0.10 |
| MACD Histogram | 0.2161 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 48.90 | ||||
| Resistance 3 (R3) | 48.10 | 44.54 | 47.52 | ||
| Resistance 2 (R2) | 44.54 | 42.43 | 44.94 | 47.06 | |
| Resistance 1 (R1) | 42.58 | 41.13 | 43.56 | 43.38 | 46.60 |
| Pivot Point | 39.02 | 39.02 | 39.51 | 39.42 | 39.02 |
| Support 1 (S1) | 37.06 | 36.91 | 38.04 | 37.86 | 34.64 |
| Support 2 (S2) | 33.50 | 35.61 | 33.90 | 34.18 | |
| Support 3 (S3) | 31.54 | 33.50 | 33.72 | ||
| Support 4 (S4) | 32.34 |
